Oxaliplatin in Combination With Infusional 5-Fluorouracil as First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Phase II Study of the Spanish Cooperative Group for the Treatment of Digestive Tumors

被引:17
作者
Benavides, Manuel [1 ]
Pericay, Carles [2 ]
Valladares-Ayerbes, Manuel [3 ]
Gil-Calle, Silvia [1 ]
Massuti, Bartomeu [4 ]
Aparicio, Jorge [5 ]
Duenas, Rosario [6 ]
Gonzalez-Flores, Encarna [7 ]
Carrato, Alfredo [8 ]
Marcuello, Eugenio [9 ]
Gomez, Auxiliadora [10 ]
Cabrera, Enrique [11 ]
Queralt, Bernardo [12 ]
Gomez, Ma Jose [13 ]
Guasch, Inmaculada [14 ]
Etxeberria, Arantxa [15 ]
Alfaro, Jordi [16 ]
Campos, Juan Manuel [17 ]
Reina, Juan Jose [18 ]
Aranda, Enrique
机构
[1] Hosp Reg Univ Carlos Haya, Secc Oncol Med, Malaga 29010, Spain
[2] Hosp Parc Tauli, Barcelona, Spain
[3] Complejo Hosp Univ, La Coruna, Spain
[4] Hosp Gen Alicante, Alicante, Spain
[5] Hosp Univ La Fe, Valencia, Spain
[6] Complejo Hosp Jaen, Jaen, Spain
[7] Hosp Virgen Las Nieves, Granada, Spain
[8] Hosp Univ Ramon & Cajal, Madrid, Spain
[9] Hosp Santa Creu & Sant, Barcelona, Spain
[10] Hosp Reina Sofia, Cordoba, Spain
[11] Hosp Virgen Los Lirios, Alicante, Spain
[12] Inst Catalan Oncol H Josep Trueta, Girona, Spain
[13] Hosp Puerta Mar, Cadiz, Spain
[14] Hosp Manresa, Barcelona, Spain
[15] Inst Oncol, Guipuzcoa, Spain
[16] Consorci Sanit Terrasca, Barcelona, Spain
[17] Hosp Arnau Vilanova, Valencia, Spain
[18] Hosp Juan Ramon, Jimenez, Huelva, Spain
关键词
Aged; Colorectal neoplasms; Comorbidity; Chemotherapy; CAPECITABINE PLUS OXALIPLATIN; MULTICENTER RANDOMIZED-TRIAL; CLINICAL-TRIALS; ADJUVANT CHEMOTHERAPY; POOLED ANALYSIS; COLON-CANCER; FLUOROURACIL; LEUCOVORIN; OLDER; IRINOTECAN;
D O I
10.1016/j.clcc.2012.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Observed efficacy and safety of oxaliplatin plus 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) in this large prospective phase II study that included patients >= 72 years with metastatic colorectal cancer and relevant concomitant diseases compare favorably with efficacy and safety results reported for this population, including regimens with biologic therapies. Background: We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC). The present study also was carried out in elderly patients to determine the efficacy and safety of the same 5-FU schedule plus oxaliplatin. Patients and Methods: Patients (aged >= 72 years old) with mCRC, measurable disease, ECOG (Eastern Cooperative Oncology Group) <= 2 and no prior treatment were treated with oxaliplatin 85 mg/m(2) plus 5-FU 3000 mg/m(2) as a 48-hour infusion every 2 weeks. Results: The study included 134 patients, of whom, 129 were eligible. The main comorbidities were hypertension (44%), diabetes (17%), and chronic obstructive pulmonary disease (11%). The OAR and disease control rate (ORR plus stable disease) were 52% and 80%, respectively. With a median follow-up of 14 months, the median progression-free survival and overall survival were 9.1 and 16.3 months, respectively. The most frequent grade 3/4 adverse events included neutropenia (16%), diarrhea (11%), and grade 3 neurotoxicity (18%). No correlation was found between efficacy or safety and comorbidities. Conclusions: To our knowledge, this is the largest phase II prospective study in elderly patients with mCRC. The observed efficacy and safety of this schedule compared favorably with those reported in this population, including regimens with monoclonal antibodies.
引用
收藏
页码:200 / 206
页数:7
相关论文
共 52 条
[1]  
Abada A., 2000, REV ONCOL, V2, P154
[2]   Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly [J].
Aparicio, T ;
Desramé, J ;
Lecomte, T ;
Mitry, E ;
Belloc, J ;
Etienney, I ;
Montembault, S ;
Vayre, L ;
Locher, C ;
Ezenfis, J ;
Artru, P ;
Mabro, M ;
Dominguez, S .
BRITISH JOURNAL OF CANCER, 2003, 89 (08) :1439-1444
[3]  
ARANDA E, 1995, CANCER-AM CANCER SOC, V76, P559, DOI 10.1002/1097-0142(19950815)76:4<559::AID-CNCR2820760404>3.0.CO
[4]  
2-O
[5]   Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer [J].
Arkenau, Hendrik-Tobias ;
Graeven, Ullrich ;
Kubicka, Stephan ;
Grothey, Axel ;
Englisch-Fritz, Christina ;
Kretzschmar, Albrecht ;
Greil, Richard ;
Freier, Werner ;
Seufferlein, Thomas ;
Hinke, Axel ;
Schmoll, Hans-Joachim ;
Schmiegel, Wolff ;
Porschen, Rainer .
CLINICAL COLORECTAL CANCER, 2008, 7 (01) :60-64
[6]   The application of the principles of geriatrics to the management of the older person with cancer [J].
Balducci, L ;
Beghe, C .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 35 (03) :147-154
[7]   Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies [J].
Cassidy, James ;
Saltz, Leonard B. ;
Giantonio, Bruce J. ;
Kabbinavar, Fairooz F. ;
Hurwitz, Herbert I. ;
Rohr, Ulrich-Peter .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (05) :737-743
[8]   PHASE-I TRIAL OF 5-DAY CONTINUOUS VENOUS INFUSION OF OXALIPLATIN AT CIRCADIAN RHYTHM-MODULATED RATE COMPARED WITH CONSTANT RATE [J].
CAUSSANEL, JP ;
LEVI, F ;
BRIENZA, S ;
MISSET, JL ;
ITZHAKI, M ;
ADAM, R ;
MILANO, G ;
HECQUET, B ;
MATHE, G .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (12) :1046-1050
[9]   Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma - Final results of the southern Italy cooperative oncology group trial 0108 [J].
Comella, P ;
Natale, D ;
Farris, A ;
Gambardella, A ;
Maiorino, L ;
Massidda, B ;
Casaretti, R ;
Tafuto, S ;
Lorusso, V ;
Leo, S ;
Cannone, M .
CANCER, 2005, 104 (02) :282-289
[10]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947